Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
With a pediatric approval in hand for Afrezza, MannKind believes that it finally has the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insu | With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insulin powder.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

The FDA has approved technosphere insulin, an inhaled form of human insulin, for children and adolescents aged 6 years and older…

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…